CNS Pharmaceuticals | Press Releases

Overview Financials & Filings Press Releases Events Corporate Governance Stock Information FAQS

Title

Date

24 June, 2025

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287

05 June, 2025

CNS Pharmaceuticals' Chief Medical Officer Sandra Silberman MD PhD to Present at the 2025 Brain Tumor Biotech Summit

16 May, 2025

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

13 May, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At The Market Under Nasdaq Rules

13 May, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel Late Stage Abeotaxane TPI 287

01 April, 2025

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

25 March, 2025

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

26 February, 2025

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

There are no press releases that match the selected filters.

View More

Stay Updated

All Press Releases
All SEC Filings
End of Day Stock Data
Weekly

At least one type of alert must be selected.

An email address is required.

Your email alerts were set.

The following alerts could not be set: